Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olverembatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 17/20 | 0.94 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | FLT3 | P36888 | 1/20 | 0.94 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.94 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.94 |
| ▸ | KIT | P10721 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olverembatinib SCHEMBL29464044 | 1.00 | ABL1 (0.94) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29652687 | 1.00 | ABL1 (0.94) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29514988 | 0.97 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL3424528 | 0.97 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29387193 | 0.97 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL14953130 | 0.96 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29515011 | 0.96 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL30456095 | 0.96 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL30456239 | 0.93 | ABL1 (0.92) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL22699129 | 0.92 | ABL1 (0.90) | ABL1FGFR1CYP2C9PDGFRACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3999056-B1 | PHARMACEUTICAL COMBINATION AND ITS USE IN THE PREVENTION AND TREATMENT OF CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2025-07-24 | — | — | US | disclosed |
| US-12233047-B2 | Pharmaceutical combination and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3741751-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Healthquest Pharma Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-2594567-B1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | GUANGZHOU HEALTHQUEST PHARMA CO LTD (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-8846671-B2 | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-30 | — | — | US | disclosed |
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzzhou Institute of Biomedicine and Health, Chineses Academy of Sciences (CN) | 2013-08-01 | — | — | US | disclosed |
| EP-2594567-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2013-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196985-A1 | HETEROCYCLIC ALKYNYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND USES THEREOF | ABCB1, VHL, ABCC1 | ABL1 23/4885FGFR1 362/4885CYP2C9 20/4885 |
| US-12233047-B2 | Pharmaceutical combination and use thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 653/4885FGFR1 729/4885CYP2C9 52/4885 |
| US-20250235426-A1 | Pharmaceutical Combination and Use Thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 640/4885FGFR1 712/4885CYP2C9 45/4885 |
| US-20220142975-A1 | Pharmaceutical Combination and Use Thereof | SLC5A6, SLC10A1, SLC26A4 | ABL1 653/4885FGFR1 729/4885CYP2C9 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.